PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

Auto Draft
Auto Draft
Elrig
Auto Draft
CPHI
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper
news

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Merck to a notable ...
Continue Reading →
news

Merck brings former executive back to lead ex-US pharmaceuticals business

Dive Brief: Merck has tapped a former executive, Joseph Romanelli, to run the company's pharmaceutical business in markets outside the U.S. after restructuring its...
Continue Reading →
news

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed results in the large study su...
Continue Reading →
news

Merck drug for chronic cough rejected by FDA

Dive Brief: The Food and Drug Administration has rejected Merck & Co's experimental drug for chronic cough, issuing the company a complete response letter for ...
Continue Reading →
news

M&A anxiety, Roche’s comeback plan and Vir’s omicron moment

The second day of the J.P. Morgan Healthcare Conference, much like the first, didn't include the type of market-moving acquisitions or announcements that might break ...
Continue Reading →
news

COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

Paxlovid and molnupiravir are the first oral treatments for COVID-19, potentially valuable new tools as the fast-spreading omicron variant fuels a sharp surge in case...
Continue Reading →
news

A worrisome safety signal slows Merck’s HIV ambitions

Currently, the world's best-selling HIV medications are made up of at least three "active ingredients." But recent years have seen increasing interest in treatments t...
Continue Reading →
news

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could h...
Continue Reading →
news

US pays $1B to nearly double supply of Merck’s COVID-19 pill

Merck is now in a race with Pfizer to capture the upside of COVID-19 pills, which could soon play an outsized role in the next phase of the pandemic and beyond. The ...
Continue Reading →
news

Merck wins UK authorization to sell first COVID-19 pill

U.K. regulators have once again moved faster than the Food and Drug Administration to approve a new medicine for COVID-19. The UK's Medicines and Healthcare products ...
Continue Reading →

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience